Compare Ambarella Inc (AMBA) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ambarella Inc vs Zoetis Inc — how do they compare? Ambarella Inc trades at $83.72 (market cap $3.64B), while Zoetis Inc trades at $72.81 (market cap $31.14B). The key difference: Zoetis Inc is far larger — about 8.6× Ambarella Inc's market cap, and Zoetis Inc pays a 2.81% dividend while Ambarella Inc pays none. Which is the better fit depends on your goals.
| AMBA | ZTS | |
|---|---|---|
Market Cap | $3.64B | $31.14B |
Sector | Technology | Health |
52-Week High | $95.51 | $156.76 |
52-Week Low | $48.65 | $71.91 |
Enterprise Value | $3.37B | $38.70B |
Dividend Yield | — | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ambarella (AMBA) trades at $83.98, up 2.36% with strong technical momentum and bullish analyst sentiment. The stock shows positive earnings momentum with three consecutive quarterly beats, though the company remains unprofitable with a -17.18% net margin. Recent news of potential acquisition talks with NXP Semiconductors and strong positioning in edge AI markets provide catalysts for growth.
The outlook remains positive with a $108.67 consensus price target representing 29% upside potential. Key risks include ongoing profitability challenges, competitive pressures in semiconductor markets, and execution risks in transitioning to AI-focused products. The company's pivot to edge AI and automotive applications offers significant growth opportunities if successfully executed.
Zoetis (ZTS) trades at $72.42, down 3.27% amid bearish technical signals and recent earnings pressure. The stock shows strong fundamentals with 27.69% net margins and 64.91% ROE, but faces headwinds from softening pet healthcare demand. Recent Q2 2026 earnings beat estimates but revenue missed, prompting a lowered 2026 outlook. Analyst consensus remains positive with a $94.90 price target despite near-term challenges.
The outlook remains cautiously optimistic given ZTS's dominant market position and profitability, though near-term performance depends on reversing companion animal segment weakness. Investment opportunity exists at current discounted valuation (P/E 12.29), balanced against competitive pressures and class action litigation risks. Upside potential aligns with analyst targets if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ambarella Inc
Ambarella is a semiconductor company specializing in low-power video compression and computer vision processors. Its chips power AI cameras for security, automotive safety, and robotics applications.
Read more on AMBA →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
